Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Nizoral AD 1% ketoconazole dandruff shampoo approved for OTC use Oct. 10.

This article was originally published in The Tan Sheet

Executive Summary

J&J OTC NIZORAL AD DANDRUFF SHAMPOO GRANTED FDA APPROVAL for the control of flaking, scaling and itching. The agency cleared Johnson & Johnson's application to switch its ketoconazole 1% shampoo (NDA 20-310) on Oct. 10. The product will be marketed by J&J Consumer Products Group. J&J will continue to sell prescription Nizoral 2% shampoo but with a new indication: treatment of tinea versicolor, a topical fungal infection.

You may also be interested in...



Johnson & Johnson President Brings Extensive McNeil Background To Post

Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years

Johnson & Johnson President Brings Extensive McNeil Background To Post

Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years

Johnson & Johnson President Brings Extensive McNeil Background To Post

Johnson & Johnson's appointment of James Lenehan, 53, as president signals a strong commitment by the company to its consumer products segments, despite the firm's shift in emphasis toward its pharmaceutical business over the past ten years

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel